Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
1.52
Aug 07 • 3:59 PM ET Dollar change+0.10 Percentage change(7.04%)
Aftermarket Close
1.50
Aftermarket • 7:37 PM ET Dollar change-0.02 Percentage change(-1.31%)
Aug 06, 10:05 AMCo-Diagnostics submits Dual 510(k) premarket notification and concurrent CLIA Waiver by Application to FDA for Co-Dx PCR Flu A/B & RSV test
Index
-
Market Cap
10.61M
Enterprise Value
4.41M
Income
-48.50M
Sales
0.51M
Book/sh
4.45
Cash/sh
1.18
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
115
IPO
Jul 12, 2017
P/E
-
Forward P/E
-
PEG
-
P/S
20.80
P/B
0.34
P/C
1.29
P/FCF
-
EV/EBITDA
-
EV/Sales
8.65
Quick Ratio
2.09
Current Ratio
2.28
Debt/Eq
0.13
LT Debt/Eq
0.07
Option/Short
No / Yes
EPS (ttm)
-28.01
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
-37.47% -
Sales past 3/5Y
-76.97% -64.54%
EPS Y/Y TTM
18.03%
Sales Y/Y TTM
-9.46%
EPS Q/Q
42.48%
Sales Q/Q
190.30%
Insider Own
5.18%
Insider Trans
0.00%
Inst Own
5.39%
Inst Trans
2.78%
ROA
-126.56%
ROE
-151.66%
ROIC
-281.74%
Gross Margin
-187.30%
Oper. Margin
-6255.15%
Profit Margin
-9438.49%
SMA20
-22.85%
SMA50
-54.59%
SMA200
-68.52%
Trades
Shs Outstand
5.28M
Shs Float
5.01M
52W High
46.50 -96.73%
52W Low
1.26 20.63%
Volatility
11.45% 13.37%
ATR (14)
0.35
RSI (14)
32.53
Beta
2.87
Rel Volume
0.04
Avg Volume
5.77M
Volume
249,647
Perf Week
5.56%
Perf Month
-42.42%
Perf Quarter
-21.24%
Perf Half Y
-35.32%
Perf YTD
-69.95%
Perf Year
-79.46%
Perf 3Y
-96.10%
Perf 5Y
-99.49%
Perf 10Y
-
Prev Close
1.42
Price
1.52
Change %
7.04%
Aug-06-26 09:30AM
Jul-30-26 09:00AM
Jul-28-26 08:00AM
Jul-22-26 09:00AM
Jul-16-26 09:00AM
09:00AM Loading…
Jul-08-26 09:00AM
Jul-01-26 09:00AM
Jun-25-26 09:00AM
Jun-18-26 09:05AM
Jun-11-26 09:00AM
Jun-02-26 09:00AM
May-26-26 01:00PM
09:00AM
May-19-26 10:54PM
10:34AM
08:30AM Loading…
May-15-26 08:30AM
01:02AM
May-14-26 04:01PM
May-11-26 05:43AM
May-08-26 09:00AM
Apr-16-26 09:00AM
Apr-14-26 09:00AM
Apr-09-26 09:00AM
Apr-02-26 09:00AM
Apr-01-26 08:30AM
Mar-31-26 11:02PM
04:01PM
Mar-25-26 08:00AM
Mar-20-26 03:30PM
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
ChairmanMr. Dwight H. Egan
PresidentMr. Richard David Abbott
CFO & Company SecretaryMr. Brian L. Brown CPA
Chief Operating OfficerMr. David Nielsen
Vice President of Finance & AccountingMr. Dan Bohrer CPA